Good transplant outcomes in hypertrophic cardiomyopathy

(HealthDay) -- Post-heart transplant survival does not differ significantly between patients with hypertrophic cardiomyopathy (HC) and those with other types of heart disease, according to a study published in the Aug. 15 issue of The American Journal of Cardiology.

To elucidate the post-transplant prognosis for patients with HC, Tomoko S. Kato, M.D., Ph.D., from Columbia University in New York City, and colleagues retrospectively reviewed 813 consecutive undergoing from 1999 to 2010. The clinical course was compared for 41 patients with idiopathic HC, 373 patients with ischemic heart disease, and 398 patients with other heart disease.

The researchers found that the HC patients were significantly younger than those with ischemic heart disease (47.8 ± 14.0 versus 57.1 ± 9.4 years). Compared with patients with ischemic heart disease or other heart disease, a significantly lower proportion of patients with HC underwent ventricular assist device surgery for bridge-to-transplant (14.6 percent versus 31.1 and 35.7 percent, respectively). Patients with HC had better post-transplant survival than that those with ischemic heart disease at one and five years (P = 0.0359), although survival did not differ significantly from those with other heart disease. Reduced post-transplant survival was seen for those with HC on univariate, but not multivariate, analyses. Most patients with HC had non-dilated left ventricles, and post-transplant survival was similar for those with dilated and non-dilated left ventricles.

"In conclusion, the post-transplant survival of those with HC did not differ from those of the subjects who underwent transplant for other non-HC indications," the authors write.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Heart transplant patients at risk for serious skin cancers

Jun 30, 2011

A new study published in the American Journal of Transplantation reveals that there is a significant risk of serious skin cancers, including cutaneous squamous cell carcinoma and melanoma, in heart transplant patients.

Recommended for you

Amgen misses 1Q views as higher costs cut profit

Apr 22, 2014

Despite higher sales, biotech drugmaker Amgen's first-quarter profit fell 25 percent as production and research costs rose sharply, while the year-ago quarter enjoyed a tax benefit. The company badly missed ...

Valeant, Ackman make $45.6B Allergan bid

Apr 22, 2014

Valeant Pharmaceuticals and activist investor Bill Ackman have unveiled details of their offer to buy Botox maker Allergan, proposing a cash-and-stock deal that could be worth about $45.6 billion.

User comments